Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 446

Results For "CE"

9352 News Found

Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
News | December 21, 2025

Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch

Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026


BPL Medical Technologies funds AI dept at Sri S Ramasamy Naidu Memorial College
News | December 21, 2025

BPL Medical Technologies funds AI dept at Sri S Ramasamy Naidu Memorial College

The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club


Gut health crisis fuelling anxiety, early ageing & lifestyle diseases
Healthcare | December 21, 2025

Gut health crisis fuelling anxiety, early ageing & lifestyle diseases

The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing


Bristol Myers Squibb to provide Eliquis free to Medicaid
News | December 21, 2025

Bristol Myers Squibb to provide Eliquis free to Medicaid

The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain


Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus
Clinical Trials | December 21, 2025

Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus

The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation


Takeda posts strong Phase 3 win for oral psoriasis drug
Clinical Trials | December 21, 2025

Takeda posts strong Phase 3 win for oral psoriasis drug

Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies


SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
R&D | December 20, 2025

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery

SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements


EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
Drug Approval | December 20, 2025

EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease

Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD